Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Current Leases (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Current Leases readings, the most recent being $1.0 million for Q1 2026.

  • On a quarterly basis, Current Leases fell 5.23% to $1.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.0 million, a 5.23% decrease, with the full-year FY2025 number at $1.0 million, down 0.96% from a year prior.
  • Current Leases hit $1.0 million in Q1 2026 for Atara Biotherapeutics, down from $1.0 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $13.0 million in Q2 2024 to a low of $832000.0 in Q1 2023.
  • Median Current Leases over the past 5 years was $1.0 million (2025), compared with a mean of $3.7 million.
  • Biggest five-year swings in Current Leases: soared 7388.89% in 2022 and later crashed 90.78% in 2024.
  • Atara Biotherapeutics' Current Leases stood at $12.8 million in 2022, then dropped by 12.04% to $11.3 million in 2023, then crashed by 90.78% to $1.0 million in 2024, then fell by 0.96% to $1.0 million in 2025, then decreased by 1.36% to $1.0 million in 2026.
  • The last three reported values for Current Leases were $1.0 million (Q1 2026), $1.0 million (Q4 2025), and $2.2 million (Q2 2025) per Business Quant data.